People · Operator
Named in public records as an officer, director or promoter · active 2019–2022 · Pharmaceuticals, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kinaset Therapeutics, Inc. | — | Pharmaceuticals | Series B | $30.0M | $437.7M | 2020 |
| Nido Biosciences, Inc. | — | Biotech / Pharma | Series B | $22.4M | $636.4M | 2019 |
Jamil Beg at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jamil Beg on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Schwab | 1 | 16 |
| Kevin Bitterman | 1 | 15 |
| Robert Clarke | 1 | 7 |
| Andrew Hedin | 1 | 5 |
| TOM KING | 1 | 4 |
| Jacqueline Grant | 1 | 3 |
| Elliot Ehrich | 1 | 2 |
| Bram Vanparys | 1 | 1 |
| Frazer Morgan | 1 | 1 |
| Roger Heerman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.